StockUS listing USPLXAMEXHealthcareValue Trap

Protalix Biotherapeutics Inc(PLX) Stock Analysis | Healthcare

USD --+0.00%
Reward38Moderate
Risk38Moderate
75%Data
Strong 24% profit margin · Revenue growing 23% YoY
USD —+0.00 (+0.00%) Previous close · AMEX
Market cap 257.17M
Reward Ratingⓘ38 Moderate reward assessment · 75% data coverage
Bottom 5% of stocksView factors
Risk Ratingⓘ38 Moderate risk assessment
Risk factors availableUnlock details

Educational tool only – Scores are based on historical data and financial metrics for informational purposes. This is not financial advice or a recommendation to buy or sell any security. Always conduct your own research or consult a qualified financial adviser.

Educational tool only · More
Limited data coverage
We don't have enough public data on PLX to score it reliably yet — Reward, Risk, Forecasts and Dividends tabs aren't available for this stock. The price chart and basic profile are still shown.
OTC / ADR stock — scores and fundamentals use data tagged in USD by our provider. The issuer may report in a different home currency (e.g. JPY), so treat figures as directional rather than precise.
Not available yet for this stock
The overview tab requires data we don't have for this stock yet. The price chart is the most reliable view we have — try the Chart tab.
Earnings Ex-dividend

Market Performance

Stock returned +10.0% over the past year, broadly in line with market conditions.

What is Protalix Biotherapeutics Inc?

, a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on the ProCellEx plant cell-based protein expression system.

AI Brief Pro

The brief on Protalix Biotherapeutics Inc

The story behind the price, the case for and against, and what could go wrong. Open a part to read it.

What is Protalix Biotherapeutics Inc?

, a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on the ProCellEx plant cell-based protein expression system. The company provides Elelyso for the treatment of Gaucher disease; and Elfabrio for the treatment of adult patients with a confirmed diagnosis of Fabry disease. The company is listed on the AMEX in USA, operating in the Healthcare sector, with a market capitalisation of 257.17M, and a P/E ratio of 12.7x.

Financial Highlights

Investment Breakdown

Growth
Revenue and earnings growing steadily, indicating improving operating performance.
Profitability
Profitability metrics are mixed — margins may be under pressure.
Risk
Risk profile appears balanced versus broad market conditions.
Valuation
Valuation appears fair relative to current fundamentals.

OpenBook Logo Analysis

Reward: Moderate (38)
Company Information
SectorHealthcare
IndustryBiotechnology
Market Cap257.17M
P/E Ratio12.7083
Beta-0.018
Insider Activity
12M windowQuiet
Fewer than three real open-market insider trades in the last 12 months. Mechanical activity (option exercises, RSU vests) is excluded from the signal.